A practical reference on lyophilized powder: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-06-03. Anything still debated is marked as such rather than presented as settled.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
化学修饰延长了分子在体内的停留时间，使较低频次的给药安排成为可能。脂肪酸侧链通过与白蛋白结合延缓清除，非天然氨基酸则降低酶解速率。这些修饰同时改变分子的溶解性与稳定性，需要在制剂设计和储存条件中一并考虑。修饰引入的免疫原性风险也属于开发过程中需要评估的项目。
该化合物处于临床试验阶段，尚未在多数地区取得上市许可。公开信息主要来自企业公告、学术会议摘要与试验注册平台记录，完整数据仍在逐步披露。关于长期疗效与安全性的判断，需要等待规模更大、随访更久的研究结果，目前不宜对最终结论作出预判。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Pharmacologically the compound activates three receptors: GLP-1, GIP, and glucagon. GLP-1 and GIP signaling contribute to glucose-dependent insulin release, delayed gastric emptying, and reduced appetite, while glucagon receptor activation is associated with increased energy expenditure and hepatic fat oxidation. The single-molecule design is intended to keep these activities in one peptide rather than combining separate agents. Relative activity at each receptor differs, and the balance between them is a central question in interpretation. The glucagon component is partly offset by incretin-mediated insulin secretion, an interaction that remains incompletely characterized.
Dissolution behavior depends on the amino acid sequence, the counterion content, and the buffer chosen. Many peptides disperse readily in water or mild aqueous buffers, while others require a small amount of organic co-solvent or a change in pH. Adsorption to plastic and glass surfaces can reduce the concentration of a solution over time, particularly at low concentrations. Filtration before analysis removes particulates, and aliquoting limits repeated freeze-thaw cycles that stress the material.
Research-grade peptide material is commonly supplied as a lyophilized powder, a form that limits degradation during transport and storage. Standard practice keeps such material cold and protected from light and moisture, with tighter conditions used for long-term archives. Once dissolved, solutions are generally considered less stable than the dry powder and are handled on shorter timescales. These established conventions derive largely from general peptide chemistry rather than from compound-specific evidence alone.
Hypertension treated with a β-blocker such as atenolol, alone or in conjunction with a thiazide diuretic, is associated with a higher incidence of new onset type 2 diabetes mellitus compared to those treated with an ACE inhibitor or angiotensin receptor blocker. β-blockers, of which atenolol is mainly studied, provides weaker protection against stroke and mortality in patients over 60 years old compared to other antihypertensive medications. Diuretics may be associated with better cardiovascular and cerebrovascular outcomes than β-blockers in the elderly. Rarely, atenolol has been associated with induction of acute delirium.
consistent, clinically established pharmacodynamic relationships between plasma drug concentrations and pharmacological efficacy and/or toxicity; significant between-patient pharmacokinetic variability, making a standard dosage achieve different concentration levels among patients (while the drug disposition remains relatively stable in a given patient); narrow therapeutic window of the drug, which forbids giving high doses in all patients to ensure overall efficacy; drug dosage optimization not achievable based on clinical observation alone; duration of the treatment and criticality for patient's condition justifying dosage adjustment efforts; potential patient compliance problems that might be remedied through concentration monitoring. TDM determinations are also used to detect and diagnose poisoning with drugs, should the suspicion arise. Examples of drugs widely analysed for therapeutic drug monitoring:
=== Insulin === Insulin resistance can vary greatly between cats. In some cases glycaemic control can be achieved with doses of 1 to 3 U/cat b.i.d., a 'normal' level of insulin dosage. Insulin levels should be increased by 0.5 to 1 U/cat b.i.d. every 5 to 7 days until glycaemic control has been achieved (blood glucose level of 100 to 300 mg/dL). Frequent monitoring of cats and dogs undergoing insulin therapy is required. Levels should not be increased higher than 15 U/cat b.i.d. for cats. In dogs insulin therapy should be initiated immediately if the blood glucose concentration is higher than >140 mg/dL or 8 mmol/L. Severity of hyperglycaemia determines the level provided, with the range for dogs being between 0.05 and 0.25 U/kg b.i.d.
"Explaining the End of the Cold War: A New Historical Consensus?" Journal of Cold War Studies - Volume 4, Number 4, Fall 2002, pp. 60–92 in Project MUSE. Trachtenberg, Marc. "The Marshall Plan as Tragedy." Journal of Cold War Studies 2005 7(1): 135–140. ISSN 1520-3972 Fulltext: in Project MUSE. Walker, J. Samuel. "Historians and Cold War Origins: The New Consensus", in Gerald K. Haines and J. Samuel Walker, eds., American Foreign Relations: A Historiographical Review (1981), 207–236. Watry, David M. Diplomacy at the Brink: Eisenhower, Churchill, and Eden in the Cold War. Baton Rouge: Louisiana State University Press, 2014. ISBN 9780807157183. Westad, Odd Arne, ed. Reviewing the Cold War: Approaches, Interpretations, Theory (2000) essays by scholars. Westad, Odd Arne, "The New International History of the Cold War: Three (Possible) Paradigms," Diplomatic History, 2000, Vol. 24 in EBSCO. Westad, Odd Arne, ed. Reviewing the Cold War: Approaches, Interpretations, Theory (2000) excerpt and text search. Westad, Odd Arne, The Cold War: A World History, Basic Books, 2017. ISBN 0465054935. White, Timothy J. "Cold War Historiography: New Evidence Behind Traditional Typographies" International Social Science Review, (2000). Xia, Yafeng. "The Study of Cold War International History in China: A Review of the Last Twenty Years," Journal of Cold War Studies10#1 Winter 2008, pp. 81–115 in Project MUSE.
Sources: en.wikipedia.org
An enlarged thyroid gland is called a goitre. Goitres are present in some form in about 5% of people, and are the result of a large number of causes, including iodine deficiency, autoimmune disease (both Graves' disease and Hashimoto's thyroiditis), infection, inflammation, and infiltrative disease such as sarcoidosis and amyloidosis. Sometimes no cause can be found, a state called "simple goitre". Some forms of goitre are associated with pain, whereas many do not cause any symptoms. Enlarged goitres may extend beyond the normal position of the thyroid gland to below the sternum, around the airway or esophagus. Goitres may be associated with hyperthyroidism or hypothyroidism, relating to the underlying cause of the goitre. Thyroid function tests may be done to investigate the cause and effects of the goitre. The underlying cause of the goitre may be treated, however many goitres with no associated symptoms are simply monitored.
In June 1911, while attending a conference in Stettin, Hahn met Edith Junghans (1887–1968), a student at the Royal School of Art in Berlin. They saw each other again in Berlin, and became engaged in November 1912. On 22 March 1913 the couple were married in Stettin, where Edith's father, Paul Ferdinand Junghans, was a high-ranking law officer and President of the City Parliament until his death in 1915. After a honeymoon at Punta San Vigilio on Lake Garda in Italy, they visited Vienna, and then Budapest, where they stayed with George de Hevesy. They had one child, Hanno Hahn, who was born on 9 April 1922. Hanno enlisted in the army in 1942, and served on the Eastern Front in World War II as a panzer commander. He lost an arm in combat. After the war he became an art historian and architectural researcher (at the Hertziana in Rome), known for his discoveries in the early Cistercian architecture of the 12th century. In August 1960, while on a study trip in France, Hanno died in a car accident, together with his wife and assistant Ilse Hahn née Pletz. They left a fourteen-year-old son, Dietrich Hahn. In 1990, the Hanno and Ilse Hahn Prize for outstanding contributions to Italian art history was established in memory of Hanno and Ilse Hahn to support young and talented art historians. It is awarded biennially by the Bibliotheca Hertziana – Max Planck Institute for Art History in Rome.
=== Stereoisomers === In addition to distinguishing tocopherols and tocotrienols by position of methyl groups, the tocopherols have a phytyl tail with three chiral points or centers that can have a right or left orientation. The naturally occurring plant form of alpha-tocopherol is RRR-α-tocopherol, also referred to as d-tocopherol, whereas the synthetic form (all-racemic or all-rac vitamin E, also dl-tocopherol) is equal parts of eight stereoisomers RRR, RRS, RSS, SSS, RSR, SRS, SRR and SSR with progressively decreasing biological equivalency, so that 1.36 mg of dl-tocopherol is considered equivalent to 1.0 mg of d-tocopherol, the natural form. Rephrased, the synthetic has 73.5% of the potency of the natural.
For services to Life Saving. Geoffrey Francis Norris, General Medical Practitioner, London. For services to Medicine. Arthur Joseph Nutter. For services to the Lieutenancy in Lancashire. John O'Neil, lately Principal Lecturer and Course Leader of PGCE Art and Design, University of Wales Institute, Cardiff. For services to Art Education and Teacher Training. Martin Offiah. For services to Rugby Football. Enid Rosalind Oliver. For services to the community in Ashford, Kent. William James Orford. For services to Cricket in the West Midlands. Vera Overs. For services to the community in Martindale, Cumbria. Clifford Owen. For services to the Chorley and District Talking Newspaper, Lancashire. Pamela Mary Owen. For services to the community, particularly the NHS, in Welshpool, Powys. Anthony Gerald Palmer. For services to the War Pensions Committee in East Anglia. Sarah Faith, The Honourable Mrs. Palmer. For services to the community, particularly the British Red Cross Society, in Berkshire. Isobel Marilyn Park. For services to the Scout Association in Dumfries. Gordon Seymour Passmore, Member, London Borough of Wandsworth. For services to Local Government. Norman Henry Pattenden, Special Operations Manager, North & South Railways Ltd. For services to the Railways Industry. William Evans Pattison. For services to Mountain Rescue. Robert John Patton. For services to the Engineering Industry. Christine Anne Pendlebury, Personal Secretary, Home Office. Philippa Helen Perks. For services to the community in Wrington, Bristol.
Acne Hair loss Increased risk of heart disease Kidney and liver dysfunction Hypertension Impotence Many prohormone supplements such as 1-testosterone were legal in the United States until reclassified as a Schedule III drug in 2005. However, many illegal prohormones like 1-testosterone are currently being sold legally and marketed by brands such as "Advanced Muscle Science" as 1-androsterone, and are labeled to contain 1-androstenedione-3b-ol,17-one. Only through a recent clinical study has it been shown that the 1-androsterone in the capsules being sold was identified using semi-quantitation and confirmed to be 1-testosterone. Research surrounding other prohormones and prohormone supplements is limited, so many side effects are unknown regarding both legal and illegal prohormone supplements.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
指同一个分子能激活 GIP、GLP-1 和胰高血糖素三类受体。它与只激活一到两种受体的同类分子在设计思路上有所区别。这种设计的目的在于覆盖更多代谢调节通路。